Meeting
2023 ASCO Annual Meeting
Assessing tumor-infiltrating immune cells and outcomes with cisplatin- versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum-treated UC cohorts.
Authors
Konrad Stawiski
Medical University of Lodz, Lodz, Poland
Konrad Stawiski , Júlia Perera-Bel , Alejo Rodriguez-Vida , Núria Juanpere Rodero , Kent William Mouw , Aristotelis Bamias , Filipe Lf Carvalho , Joaquim Bellmunt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4583)
DOI
10.1200/JCO.2023.41.16_suppl.4583
Abstract #
4583
Poster Bd #
75
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing.
First Author: Ali Raza Khaki
Poster
2019 Genitourinary Cancers Symposium
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for overall survival in men with advanced prostate cancer treated with platinum chemotherapy.
First Author: Panagiotis J. Vlachostergios
Poster
2017 ASCO Annual Meeting
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.
First Author: Thomas Powles
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu